BACKGROUND AND PURPOSE: Ovariectomy accelerates age-related skin changes as adequate oestrogen levels are required to control structural integrity and functional capacity of skin. Genistein, a soy-derived isoflavone, has been tested in anti-ageing cosmetic preparations with interesting results on skin elasticity, photoaging and skin cancer prevention. We investigated the effects of genistein aglycone and compared them with systemic raloxifene hydrochloride and 17-α-ethinyloestradiol on skin changes in aged, ovariectomized (OVX) rats. EXPERIMENTAL APPROACH: Six months after ovariectomy, rats were randomly allocated to different groups and treated, daily, with genistein aglycone (1 and 10mg·kg(-1) s.c.), raloxifene hydrochloride (0.05 and 0.5mg·kg(-1) s.c.) or 17-α-ethinyloestradiol (0.003 and 0.03mg·kg(-1) s.c.) for 12 weeks. Controls were untreated OVX and sham OVX rats. At the end of the treatment period, a skin biopsy was carried out and skin samples were assessed for molecular, histological and functional changes. KEY RESULTS: Skin samples of untreated OVX rats showed a decrease in TGF-β1, VEGF, MMP-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 compared with sham OVX rats. All the treatments significantly restored this depressed molecular profile revealed in OVX rats. Genistein aglycone, 1mg·kg(-1) , also significantly increased the thickness of collagen and breaking strength of skin in the OVX rats. CONCLUSIONS AND IMPLICATIONS: Relatively long-term, systemic treatment with genistein aglycone shows comparable efficacy to oestrogen in reversing some molecular, histological and functional changes of the skin associated with ovariectomy in aged rats. This suggests that genistein aglycone might be an effective alternative therapy for the management of age-related skin changes in postmenopausal women.
BACKGROUND AND PURPOSE: Ovariectomy accelerates age-related skin changes as adequate oestrogen levels are required to control structural integrity and functional capacity of skin. Genistein, a soy-derived isoflavone, has been tested in anti-ageing cosmetic preparations with interesting results on skin elasticity, photoaging and skin cancer prevention. We investigated the effects of genistein aglycone and compared them with systemic raloxifene hydrochloride and 17-α-ethinyloestradiol on skin changes in aged, ovariectomized (OVX) rats. EXPERIMENTAL APPROACH: Six months after ovariectomy, rats were randomly allocated to different groups and treated, daily, with genistein aglycone (1 and 10mg·kg(-1) s.c.), raloxifene hydrochloride (0.05 and 0.5mg·kg(-1) s.c.) or 17-α-ethinyloestradiol (0.003 and 0.03mg·kg(-1) s.c.) for 12 weeks. Controls were untreated OVX and sham OVX rats. At the end of the treatment period, a skin biopsy was carried out and skin samples were assessed for molecular, histological and functional changes. KEY RESULTS: Skin samples of untreated OVX rats showed a decrease in TGF-β1, VEGF, MMP-2, MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 and TIMP-2 compared with sham OVX rats. All the treatments significantly restored this depressed molecular profile revealed in OVX rats. Genistein aglycone, 1mg·kg(-1) , also significantly increased the thickness of collagen and breaking strength of skin in the OVX rats. CONCLUSIONS AND IMPLICATIONS: Relatively long-term, systemic treatment with genistein aglycone shows comparable efficacy to oestrogen in reversing some molecular, histological and functional changes of the skin associated with ovariectomy in aged rats. This suggests that genistein aglycone might be an effective alternative therapy for the management of age-related skin changes in postmenopausal women.
Authors: Robert W Hsieh; Shyamala S Rajan; Sanjay K Sharma; Yuee Guo; Eugene R DeSombre; Milan Mrksich; Geoffrey L Greene Journal: J Biol Chem Date: 2006-04-28 Impact factor: 5.157
Authors: Eui Dong Son; Jin Young Lee; Serah Lee; Mi Sun Kim; Byeong Gon Lee; Ih Seoup Chang; Jin Ho Chung Journal: J Invest Dermatol Date: 2005-06 Impact factor: 8.551
Authors: Young H Ju; Daniel R Doerge; Kimberly F Allred; Clinton D Allred; William G Helferich Journal: Cancer Res Date: 2002-05-01 Impact factor: 12.701
Authors: G Murphy; V Knäuper; S Cowell; R Hembry; H Stanton; G Butler; J Freije; A M Pendás; C López-Otín Journal: Ann N Y Acad Sci Date: 1999-06-30 Impact factor: 5.691
Authors: H Marini; A Bitto; D Altavilla; B P Burnett; F Polito; V Di Stefano; L Minutoli; M Atteritano; R M Levy; N Frisina; S Mazzaferro; A Frisina; R D'Anna; F Cancellieri; M L Cannata; F Corrado; C Lubrano; R Marini; E B Adamo; F Squadrito Journal: Nutr Metab Cardiovasc Dis Date: 2009-07-23 Impact factor: 4.222
Authors: G G Kuiper; J G Lemmen; B Carlsson; J C Corton; S H Safe; P T van der Saag; B van der Burg; J A Gustafsson Journal: Endocrinology Date: 1998-10 Impact factor: 4.736
Authors: Tao Liu; Nan Li; Yi-Qi Yan; Yan Liu; Ke Xiong; Yang Liu; Qing-Mei Xia; Han Zhang; Zhi-Dong Liu Journal: Phytother Res Date: 2019-11-20 Impact factor: 5.878
Authors: Jan Pitha; Martina Huttl; Hana Malinska; Denisa Miklankova; Hana Bartuskova; Tomas Hlinka; Irena Markova Journal: Int J Mol Sci Date: 2022-03-04 Impact factor: 5.923
Authors: Cyril Statzer; Elisabeth Jongsma; Sean X Liu; Alexander Dakhovnik; Franziska Wandrey; Pavlo Mozharovskyi; Fred Zülli; Collin Y Ewald Journal: Aging Cell Date: 2021-08-04 Impact factor: 9.304